Glenmark Pharmaceuticals Launches GLIPIQ Ⓡ (Semaglutide) in India, Setting New Affordability Benchmark
Mumbai, India, March 21, 2026: Glenmark Pharmaceuticals Ltd (Glenmark) announced the launch of GLIPIQ Ⓡ (semaglutide) in India for the management of Type 2 Diabetes Mellitus (T2DM). The launch aims to improve affordability and expand access to advanced diabetes treatment for patients.GLIPIQ Ⓡ is available in both vial and pre-filled pen formulations and has been approved by the Central Drugs Standard Control Organization (CDSCO) following a Phase III clinical study in India. The vial-based formulation, with dose-specific syringes, is intended to offer a more accessible and flexible approach to GLP-1 therapy and a cost-effective treatment pathway.
The expected weekly cost of treatment with GLIPIQ Ⓡ vials ranges from ₹325 to ₹440. The product is available in strengths of 2 mg/1.5 mL, 4 mg/3 mL, and 8 mg/3 mL.
Glenmark is also introducing 'Sankalp,' a patient support program (PSP) designed to support therapy initiation, improve comfort with injectable treatment, and enable long-term adherence.
“With GLIPIQ Ⓡ , we are setting a new benchmark in affordability for GLP-1 therapy, with weekly treatment starting at ₹325,” said Mr. Alok Malik, President and Business Head, India Formulations, Glenmark Pharmaceuticals Ltd. “The vial-based format enables us to offer a more affordable option while supporting clinically guided initiation and flexible dosing.”
Semaglutide is a GLP-1 receptor agonist used in the management of Type 2 Diabetes, particularly in patients with comorbidities such as obesity, atherosclerotic cardiovascular disease (ASCVD), heart failure with preserved ejection fraction (HFpEF), and chronic kidney disease (CKD).
Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a research-led pharmaceutical company with manufacturing facilities across four continents and a commercial footprint in 80+ countries.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.